Shares of Tonix Pharmaceuticals
TNXP,
fell Tuesday after the corporate stated it could discontinue growth of its remedy for main depressive dysfunction.
The inventory was down 29%, to 42 cents, in after-hours buying and selling, following a 3% rise at Tuesday’s shut. Shares are down 76% this 12 months.
The Chatham, N.J.-based pharmaceutical firm stated {that a} research of TNX-601 ER, its melancholy remedy, had not met its major efficacy endpoint, and had not proven a clinically or statistically significant impact on melancholy severity.
The proof-of-concept trial concerned 132 sufferers, all of whom acquired the oral formulation of tianeptine designed for day by day dosing.
Source web site: www.marketwatch.com
